FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285395744> ?p ?o ?g. }

• W4285395744 endingPage "743" @default.
• W4285395744 startingPage "737" @default.
• W4285395744 abstract "Introduction: Heparin resistance has been reported in coronavirus disease 2019 (COVID-19) patients receiving intravenous unfractionated heparin (IV UFH). Anti-Xa monitoring of IV UFH has been suggested over activated partial thromboplastin times due to laboratory interference from elevated factor VIII and fibrinogen levels in COVID-19 patients. Information on heparin resistance with anti-Xa monitoring in COVID-19 patients with confirmed venous thromboembolism (VTE) is lacking. Methods: In this retrospective cohort study of patients with radiographically confirmed VTE, IV UFH dosage requirements in COVID-19 positive patients were compared with COVID-19 negative patients. The primary endpoint was the IV UFH dose needed to achieve a therapeutic anti-Xa level. Secondary endpoints included time to therapeutic anti-Xa, number of dose adjustments to achieve therapeutic anti-Xa, and bleeding. Results: Sixty-four patients with confirmed VTE were included (20 patients COVID-19 positive, 44 patients COVID-19 negative). Eighty-five percent (17 of 20) of COVID-19 positive patients achieved anti-Xa ≥ 0.3 units/mL with the first anti-Xa level drawn post-IV UFH infusion initiation. The median UFH dose needed to achieve first therapeutic anti-Xa was similar between COVID-19 positive and COVID-19 negative patients (median [IQR]: 18 units/kg/hour [18-18] vs 18 units/kg/hour [18-18], P = .423). The median number of dose adjustments and time to achieve therapeutic anti-Xa were also similar between the 2 groups. The frequency of patients receiving IV UFH of more 35 000 units/day did not differ between the 2 groups. Two cases of clinically significant heparin resistance in the COVID-19 positive group were identified. Conclusions: During the first wave of COVID-19, heparin dose and time to therapeutic anticoagulation appeared to be similar between COVID-19 positive and COVID-19 negative patients monitored by anti-Xa at our institution. More studies are required to evaluate clinically significant heparin resistance in the context of the wide range of viral variants which developed, and beyond the population observed in this single center retrospective study." @default.
• W4285395744 created "2022-07-14" @default.
• W4285395744 creator A5012735309 @default.
• W4285395744 creator A5043451552 @default.
• W4285395744 creator A5074477052 @default.
• W4285395744 creator A5074744180 @default.
• W4285395744 creator A5087704788 @default.
• W4285395744 date "2022-07-13" @default.
• W4285395744 modified "2023-10-02" @default.
• W4285395744 title "Heparin Resistance in SARS-CoV-2 Infected Patients with Venous Thromboembolism" @default.
• W4285395744 cites W2100034967 @default.
• W4285395744 cites W2103247642 @default.
• W4285395744 cites W2137920545 @default.
• W4285395744 cites W2808289730 @default.
• W4285395744 cites W2944752046 @default.
• W4285395744 cites W3016595631 @default.
• W4285395744 cites W3016764831 @default.
• W4285395744 cites W3022564719 @default.
• W4285395744 cites W3026400664 @default.
• W4285395744 cites W3033410825 @default.
• W4285395744 cites W3033755862 @default.
• W4285395744 cites W3047959517 @default.
• W4285395744 cites W3136016654 @default.
• W4285395744 cites W3154923914 @default.
• W4285395744 cites W3194687464 @default.
• W4285395744 cites W3202637221 @default.
• W4285395744 cites W3205387447 @default.
• W4285395744 cites W4205922819 @default.
• W4285395744 cites W4231969161 @default.
• W4285395744 doi "https://doi.org/10.1177/00185787221111743" @default.
• W4285395744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36340634" @default.
• W4285395744 hasPublicationYear "2022" @default.
• W4285395744 type Work @default.
• W4285395744 citedByCount "1" @default.
• W4285395744 countsByYear W42853957442023 @default.
• W4285395744 crossrefType "journal-article" @default.
• W4285395744 hasAuthorship W4285395744A5012735309 @default.
• W4285395744 hasAuthorship W4285395744A5043451552 @default.
• W4285395744 hasAuthorship W4285395744A5074477052 @default.
• W4285395744 hasAuthorship W4285395744A5074744180 @default.
• W4285395744 hasAuthorship W4285395744A5087704788 @default.
• W4285395744 hasConcept C126322002 @default.
• W4285395744 hasConcept C203092338 @default.
• W4285395744 hasConcept C2777557582 @default.
• W4285395744 hasConcept C2778261982 @default.
• W4285395744 hasConcept C2778382381 @default.
• W4285395744 hasConcept C2779036427 @default.
• W4285395744 hasConcept C2779134260 @default.
• W4285395744 hasConcept C3008058167 @default.
• W4285395744 hasConcept C524204448 @default.
• W4285395744 hasConcept C535046627 @default.
• W4285395744 hasConcept C71924100 @default.
• W4285395744 hasConcept C90924648 @default.
• W4285395744 hasConceptScore W4285395744C126322002 @default.
• W4285395744 hasConceptScore W4285395744C203092338 @default.
• W4285395744 hasConceptScore W4285395744C2777557582 @default.
• W4285395744 hasConceptScore W4285395744C2778261982 @default.
• W4285395744 hasConceptScore W4285395744C2778382381 @default.
• W4285395744 hasConceptScore W4285395744C2779036427 @default.
• W4285395744 hasConceptScore W4285395744C2779134260 @default.
• W4285395744 hasConceptScore W4285395744C3008058167 @default.
• W4285395744 hasConceptScore W4285395744C524204448 @default.
• W4285395744 hasConceptScore W4285395744C535046627 @default.
• W4285395744 hasConceptScore W4285395744C71924100 @default.
• W4285395744 hasConceptScore W4285395744C90924648 @default.
• W4285395744 hasIssue "6" @default.
• W4285395744 hasLocation W42853957441 @default.
• W4285395744 hasLocation W42853957442 @default.
• W4285395744 hasOpenAccess W4285395744 @default.
• W4285395744 hasPrimaryLocation W42853957441 @default.
• W4285395744 hasRelatedWork W1910821792 @default.
• W4285395744 hasRelatedWork W1963820157 @default.
• W4285395744 hasRelatedWork W1990662410 @default.
• W4285395744 hasRelatedWork W2017892344 @default.
• W4285395744 hasRelatedWork W2317139092 @default.
• W4285395744 hasRelatedWork W2355380694 @default.
• W4285395744 hasRelatedWork W2369002176 @default.
• W4285395744 hasRelatedWork W2377919110 @default.
• W4285395744 hasRelatedWork W2412661101 @default.
• W4285395744 hasRelatedWork W2805539024 @default.
• W4285395744 hasVolume "57" @default.
• W4285395744 isParatext "false" @default.
• W4285395744 isRetracted "false" @default.
• W4285395744 workType "article" @default.